Introduction {#s1}
============

Protein kinases have become the number one drug target of the 21th century ([@bib21]; [@bib43]), due to their central role in cellular processes and involvement in various types of cancer ([@bib17]; [@bib37]; [@bib50]). Despite their therapeutic significance, the development of specific kinase inhibitors proves to be extremely challenging because they must discriminate between the very similar active sites of a large number of kinases in human cells. One of the biggest success stories is Gleevec: a highly selective drug that specifically targets Abl kinase, providing an efficient treatment of chronic myelogenous leukemia (CML) and minimizing side effects ([@bib45]). Despite being a multi-billion-dollar cancer drug, the mechanism responsible for its impressive selectivity has been elusive until recently. Seminal work by the Kuriyan lab demonstrated that Gleevec can only bind to an inactive DFG (for Asp-Phe-Gly) loop conformation in the 'out-conformation' due to steric clash of the active, DFG-*in* conformation ([@bib71]; [@bib78]; [@bib80]). Since then it has long been proposed that the conformational state of the fully-conserved DFG loop ([@bib84]) dictates the selectivity for Gleevec and other kinase inhibitors ([@bib62]; [@bib71]; [@bib78]; [@bib85]; [@bib94]). The orientation of the DFG-motif and its possible steric clashes is indeed important for the ability of a class of inhibitors to bind to the kinase, but proved insufficient to explain drug selectivity and affinity. Earlier elegant work on Src and Abl recognized this and explored other hypotheses (e.g., differences in drug-binding pocket, energetic changes remote from the binding site and a conformational-selection mechanism) to reconcile the differences in Gleevec binding ([@bib26]; [@bib59]; [@bib80]; [@bib81]), but without conclusive success. Recent quantitative binding kinetics combined with ancestral sequence reconstruction put forward a mechanism where an induced-fit step after drug binding is the key determinant for Gleevec's selectivity ([@bib3]; [@bib89]), and fully recapitulates the binding affinities.

Here we ask the question whether this fundamentally different mechanism is a more general principle for drug efficacy and selectivity not only for Tyr kinases such as Abl, but also for Ser/Thr kinases. To this end, we chose the Ser/Thr kinase Aurora A and investigated the binding kinetics of three distinct kinase drugs: Danusertib, AT9283, and Gleevec. Aurora A kinase is one of the key regulators of mitotic events, including mitotic entry, centrosome maturation and spindle formation ([@bib36]; [@bib63]; [@bib65]), as well as assisting in neuronal migration ([@bib73]). Aurora A has attracted significant attention for the development of targeted agents for cancer because it is overexpressed in a wide range of tumors, including breast, colon, ovary and skin malignancies ([@bib17]; [@bib37]; [@bib50]; [@bib61]; [@bib66]). The focus was mainly on ATP-competitive inhibitors, but more recently inhibition by allosteric compounds has also been pursued with the aim of achieving higher selectivity ([@bib4]; [@bib10]; [@bib14]; [@bib46]; [@bib68]). So far, only the clinical significance of Aurora A inhibition by ATP-competitive drugs has been established ([@bib8]; [@bib13]), but little is known about their binding mechanisms. Many high-resolution X-ray structures of Aurora A kinase bound to different inhibitors have been solved ([@bib9]; [@bib29]; [@bib33]; [@bib34]; [@bib42]; [@bib44]; [@bib51]; [@bib64]; [@bib95]), but the selectivity profile of those kinase inhibitors remains very difficult to explain.

The drugs used in this study are small, ATP-competitive inhibitors. Danusertib (PHA739358) and AT9283 were developed for Aurora kinases, whereas Gleevec is selective for the Tyr kinase Abl. Danusertib inhibits all members of the Aurora family with low nanomolar IC~50~ values (13, 79 and 61 nM for Aurora A, B and C, respectively) ([@bib16]; [@bib35]) and was one of the first Aurora kinase inhibitors to enter phase I and II clinical trials ([@bib53]; [@bib83]). A crystal structure of Danusertib bound to Aurora A kinase shows an inactive kinase with the DFG-loop in the *out* conformation ([@bib33]). AT9283 inhibits both Aurora A and B with an IC~50~ of 3 nM ([@bib44]) and has also entered several clinical trials ([@bib13]). Interestingly, the crystal structure of Aurora A with AT9283 shows that this drug binds to the DFG*-in*, active conformation of the kinase ([@bib44]). Both drugs are high-affinity binders that reportedly bind to a discrete kinase conformation and would allow us to probe for a conformational-selection step. Lastly, we selected Gleevec as a drug that is not selective for Aurora A and should, therefore, have a weaker binding affinity. We reasoned that this choice of inhibitors could reveal general mechanisms underlying drug selectivity and affinity.

The combination of X-ray crystallography, NMR spectroscopy and comprehensive analysis of drug binding and release kinetics delivered a general mechanistic view. Differential drug affinity is not rooted in the overwhelmingly favored paradigm of the DFG-conformation, but instead in the dynamic personality of the kinase that is manifested in conformational changes after drug binding. Notably, such conformational changes have evolved for its natural substrates, and the drugs take advantage of this built-in protein dynamics.

Results {#s2}
=======

Dephosphorylated Aurora A samples both an inactive and active structure {#s2-1}
-----------------------------------------------------------------------

A plethora of X-ray structures and functional assays led to the general notion that dephosphorylated Aurora A and, more universally, Ser/Thr kinases are in an inactive conformation and that phosphorylation or activator binding induces the active structure. A comparison of many X-ray structures of inactive and active forms of Ser/Thr kinases resulted in an elegant proposal of the structural hallmarks for the active state by Taylor and collaborators: the completion of both the regulatory and catalytic spines spanning the N- and C-terminal domains, including the orientation of the DFG-motif ([@bib54]; [@bib55]). X-ray structures, however, provide merely static snapshots of possible kinase conformations that do not necessarily reflect the situation in solution. In fact, recent experimental data postulate that phosphorylation of Aurora A does not 'lock' the kinase in the active conformation, and that the activation-loop still exhibits conformational dynamics ([@bib38]; [@bib76]). On the other hand, X-ray crystallography provides high-resolution structural data that cannot readily be obtained from FRET or EPR and IR spectroscopy.

Two crystals from the same crystallization well capture both the inactive and active conformations of dephosphorylated Aurora A bound with AMPPCP ([Figure 1A,B](#fig1){ref-type="fig"}). As anticipated, the first structure (PDB 4C3R \[[@bib97]\]) superimposes with the well-known inactive, dephosphorylated Aurora A structure (PDB 1MUO \[[@bib18]\]) and the activation loop is not visible as commonly observed for kinases lacking phosphorylation of the activation loop ([@bib97]). The second structure (PDB 6CPF; [Table 1](#table1){ref-type="table"}) adopts the same conformation as the previously published phosphorylated, active structure (PDB 1OL7 \[[@bib11]\]) ([Figure 1C](#fig1){ref-type="fig"}) and the first part of the activation loop could be built, although the B-factors are high. Every hallmark of an active state is seen for this dephosphorylated protein, including the DFG-*in* conformation that is essential for completing the regulatory spine. In contrast, the DFG-loop is in the *out* position for the inactive form of Aurora A ([Figure 1D](#fig1){ref-type="fig"}, cyan). In the active, non-phosphorylated structure, electron density is seen in the canonical tighter Mg^2+^-binding site, where the metal ion is coordinated to the α- and β-phosphates of AMPPCP and Asp274. The presence of the metal is supported by the CheckMyMetal ([@bib96]) validation, except that the coordination is incomplete. We surmise that two water molecules, not visible in our data, complete the coordination sphere as is seen in several higher-resolution structures. In the inactive structure, no electron density for Mg^2+^ can be identified possibly due to the fact that Asp274 is rotated to the DFG-*out* position and is, therefore, lost as coordination partner. Furthermore, sampling of the active conformation does not depend on AMPPCP binding as dephosphorylated, apo Aurora A also crystallizes in the active form (PDB 6CPE; [Figure 1E,F](#fig1){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). Our results are consistent with other crystallographic studies on wild-type, dephosphorylated Aurora A in its apo or nucleotide bound state, where the kinase was also found in the active conformation ([@bib40]; [@bib46]; [@bib74]).

![Dephosphorylated Aurora A samples both the active and inactive conformation.\
(**A**) Superposition of X-ray structures of dephosphorylated Aurora A (residues 122--403) with Mg^2+^·AMPPCP (AMPPCP in gray sticks and magnesium as yellow sphere) in the inactive (cyan, PDB 4C3R \[[@bib97]\]) and active (orange, PDB 6CPF) state, solved from crystals of the same crystallization well. (**B**) Zoom-in of (**A**) to visualize the nucleotide binding region (K162, D274, and E181), the R-spine (L196, Q185, F275, H254, and D311) and the activation loop region (D256, K258, and T292). (**C**) Same zoom-in as in (**B**), but dephosphorylated Aurora A in active state (orange) is superimposed with phosphorylated Aurora A (red, PDB 1OL7 \[[@bib11]\]). (**D**) Superposition of the DFG(W) motif in the three states shown in (**B**) and (**C**). (**E**) Superposition of phosphorylated Aurora A in active conformation (red) and apo, dephosphorylated Aurora A also in the active conformation (yellow, PDB 6CPE). (**F**) Zoom-in of (**E**) showing the same region as in (**B**).](elife-36656-fig1){#fig1}
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###### Data collection and refinement statistics for dephosphorylated Aurora A (122-403).

  ------------------------------------------------------------------------------------------------------------
                        apo-Aurora A\                Aurora A + AMPPCP\           Aurora A + Mb + AT9283\
                        (6CPE)                       (6CPF)                       (6CPG)
  --------------------- ---------------------------- ---------------------------- ----------------------------
  Data collection                                                                 

  Space group           P 61 2 2                     P 61 2 2                     P 21 21 21

  Cell dimensions                                                                 

  *a*, *b*, *c* (Å)     80.55, 80.55, 169.79         81.75, 81.75, 172.87         63.86, 69.7, 175.56

  *α, β, γ* (°)         90, 90, 120                  90, 90, 120                  90, 90, 90

  Resolution (Å)        84.90--2.45 (2.55--2.45)\*   86.44--2.30 (2.39--2.30)\*   43.14--2.80 (2.87--2.80)\*

  *R*~meas~             0.073 (1.308)                0.113 (2.260)                0.189 (1.268)

  *I/*σ(*I*)            15.0 (1.6)                   10.3 (1.3)                   8.9 (1.1)

  *CC*~1/2~             0.998 (0.711)                0.997 (0.465)                0.986 (0.625)

  Completeness (%)      99.9 (100)                   100 (100)                    99.2 (98.8)

  Redundancy            7.6 (6.3)                    9.7 (7.8)                    5.4 (5.3)

                                                                                  

  Refinement                                                                      

  Resolution (Å)        64.52--2.45                  54.79--2.30                  36.17--2.80

  No. reflections       12617 (1224)                 15756 (1527)                 19556 (1845)

  *R*~work~/*R*~free~   0.2151/0.2528                0.2179/0.2587                0.2792/0.3350

  No. atoms                                                                       

  Protein               2035                         2055                         5122

  Ligand/ion            11                           32                           56

  Water                 4                            6                            

  *B* factors                                                                     

  Protein               71.83                        63.68                        78.84

  Ligand/ion            75.77                        76.44                        81.05

  Water                 52.52                        45.84                        

  R.m.s. deviations                                                               

  Bond lengths (Å)      0.005                        0.004                        0.003

  Bond angles (°)       0.98                         0.97                         0.98
  ------------------------------------------------------------------------------------------------------------

The number of crystals for each structure is one for apo-Aurora A and Aurora A + AMPPCP and two crystals for Aurora A + Mb + AT9283.

\*Values in parentheses are for highest-resolution shell.

We note that in Aurora kinase sequences a tryptophan residue, Trp277, is immediately following the DFG motif and displays a drastically different orientation whether Aurora A is in an active (DFG*-in*) or inactive (DFG-*out*) conformation ([Figure 1D](#fig1){ref-type="fig"}). This Trp moiety is unique for the Aurora kinase family in the Ser/Thr kinome and its position is suggested to be important for tuning the substrate specificity ([@bib19]). We used this Trp residue as probe to monitor the DFG flip and drug binding in real time as described below.

The fact that the inactive and active states are seen in the crystal implies that both are sampled; however, it does not deliver information about the relative populations or interconversion rates. Therefore, we set out to monitor the conformational exchange of the DFG-*in*/*out* flip in solution. Owing to the reported importance of the DFG flip for activity, regulation and drug design, there have been extensive efforts to characterize this conformational equilibrium by computation ([@bib5]; [@bib6]; [@bib69]; [@bib70]; [@bib77]; [@bib82]). The general notion of these computational studies is that in the absence of phosphorylation the inactive form of the kinase is most favored, in agreement with experimental evidence. Nevertheless, short-lived excursions to the active state are observed.

As an experimental approach, NMR spectroscopy is an obvious choice; however efforts on several Ser/Thr and Tyr kinases led to the general conclusion that the activation loop, including the DFG motif and most of the active-site residues, cannot be detected due to exchange broadening, and at best can only be seen after binding of drugs that stabilize conformations ([@bib15]; [@bib57]; [@bib86]; [@bib87]).

\[^1^H-^15^N\]-TROSY-HSQC experiments on uniformly ^15^N-labeled samples of Aurora A proved to be no exception: many peaks are missing and only three out of four tryptophan side chain indole signals are seen in the 2D spectra of a \[^15^N\]-Trp labeled sample ([Figure 2A,B](#fig2){ref-type="fig"}). Therefore, we sought a strategy to overcome this general problem of exchange broadening that hampers the detection of the DFG equilibrium. Aurora A was produced containing 5-fluoro-tryptophan residues to allow for one-dimensional ^19^F spectroscopy to deal with exchange broadening while providing sensitivity close to proton NMR ([@bib52]). Now, we observe as expected four peaks in our NMR spectra for apo- and AMPPCP-bound wild-type Aurora A ([Figure 2C](#fig2){ref-type="fig"}). A deconvolution of the spectrum yields almost identical integral values for all four peaks, whereas the linewidth of one resonance is approximately 5-fold larger ([Figure 2D](#fig2){ref-type="fig"}, purple signal). This broad peak is a prime candidate to originate from Trp277, directly adjacent to the DFG-loop. The W277L mutation confirmed our hypothesis ([Figure 2C](#fig2){ref-type="fig"}), and the extensive line broadening of this signal in a one-dimensional spectrum is consistent with its absence in the \[^1^H,^15^N\]-TROSY-HSQC spectrum. Of note, the W277L mutant is still active, as confirmed by a kinase assay, most likely because this Trp is not conserved in Ser/Thr kinases, where a Leu residue is found at that position for several Ser/Thr family members. Mutating any of the other, more conserved Trp residues resulted in insoluble proteins. The broad line shape for the Trp277 peak hints at severe exchange broadening in the surrounding of the DFG-loop and is consistent with the high B-factors for Trp277 and its neighboring residues observed in all crystal structures described here. Determination of relative populations and rate constants of interconversion is not possible from this data, but this missing piece of information was obtained by stopped-flow kinetics of drug binding.

![NMR spectra indicate extensive dynamics of the DFG-loop.\
(**A**) The four tryptophan residues in Aurora A are shown on the structure (PDB 4C3R \[[@bib97]\]) in stick representation; Trp277 in the DFGW-loop is highlighted in red. (**B**) Overlay of \[^1^H-^15^N\]-TROSY-HSQC spectra of dephosphorylated Aurora A in its apo-state (U-\[^15^N\], blue; \[^15^N\]-Trp, green) and AMPPCP-bound (U-\[^15^N\], red). Only three instead of the four expected cross peaks for tryptophan side chains are detected. (**C**) ^19^F NMR spectra of 5-fluoro-Trp labeled dephosphorylated wild-type Aurora A (apo in blue and AMPPCP-bound in red) and the W277L Aurora A mutant bound to AMPPCP (green). The assignment of Trp277 following the DFG-loop is shown. (**D**) ^19^F spectrum of wild-type Aurora A bound to AMPPCP (red) together with its deconvolution into four Lorentzian line shapes, the overall fit is shown as a black, dotted line. The integrals for all four signals are equal, but the linewidth for Trp277 (purple) is approximately 5-fold larger.](elife-36656-fig2){#fig2}

Gleevec binding to Aurora A distinguishes conformational selection versus induced-fit mechanisms {#s2-2}
------------------------------------------------------------------------------------------------

Through groundbreaking experiments on the Tyr kinases Abl and Src, the concept of drug selectivity based on the DFG-loop conformation has received considerable attention in kinase drug discovery ([@bib62]; [@bib85]). A recent report provides kinetic evidence for such conformational selection, but identifies an induced-fit step after drug binding as the overwhelming contribution for Gleevec selectivity towards Abl compared to Src ([@bib3]). Here, we ask the obvious question if this mechanism of Gleevec binding to Abl might exemplify a more general mechanism for kinase inhibitors.

To assess which kinetic steps control drug affinity and selectivity, we first studied the binding kinetics for Gleevec to Aurora A by stopped-flow spectroscopy using intrinsic tryptophan fluorescence under degassing conditions to reduce photobleaching. At 25°C, the binding of Gleevec to Aurora A was too fast to be monitored and, therefore, experiments were performed at 10°C. Binding kinetics of Gleevec to Aurora A exhibited biphasic kinetic traces ([Figure 3A](#fig3){ref-type="fig"}). The first, fast phase is characterized by a decrease in the fluorescence intensity ([Figure 3A,B](#fig3){ref-type="fig"}), with an observed rate constant, $k_{obs}$, increasing linearly with Gleevec concentration ([Figure 3C](#fig3){ref-type="fig"}). The slope corresponds to the bimolecular rate constant, $k_{2}$ = 1.1 ± 0.3 μM^−1^s^−1^, of Gleevec binding to Aurora A and the dissociation of Gleevec is determined from the intercept, $k_{- 2}$ = 31 ± 2 s^−1^ ([Figure 3C](#fig3){ref-type="fig"}). We note that the parameters for the physical binding step are comparable to the ones obtained for Gleevec binding to Abl (*cf.* $k_{2}$ = 1.5 ± 0.1 μM^−1^s^−1^ and $k_{- 2}$ = 25 ± 6 s^−1^, measured at 5°C) ([@bib3]). The second, slow phase exhibits an increase in fluorescence intensity ([Figure 3A](#fig3){ref-type="fig"}), with the observed rate constant decreasing with Gleevec concentration ([Figure 3D](#fig3){ref-type="fig"}). The decreasing $k_{obs}$ provides unequivocal evidence of conformational selection, where its rate of interconversion is slower than the rate of ligand dissociation ($k_{1} + k_{- 1}{\ll k}_{- 2}$). The values of $k_{1}$ and $k_{- 1}$ can be estimated by fitting the data to [Equation 1](#equ1){ref-type="disp-formula"} and are 0.014 ± 0.001 s^−1^ and 0.011 ± 0.002 s^−1^, respectively ([Figure 3D](#fig3){ref-type="fig"}). These rate constants represent the conformational change from DFG-*in* to -*out* and vice versa since Gleevec is a DFG-*out* selective inhibitor due to steric hindrance ([@bib71]; [@bib78]; [@bib80]).

![Kinetics of Gleevec binding to Aurora A at 10°C measured by stopped-flow Trp fluorescence to dissect all binding steps.\
(**A**) Kinetics after mixing 0.5 µM Aurora A with 4.5 µM Gleevec is double exponential with a fast decrease and a slow increase in fluorescence signal. (**B**) The decrease in fluorescence intensity due to the fast binding phase was completed within 0.25 s. (**C**) Observed rate constants of fast binding phase were plotted against increasing concentrations of Gleevec ($k_{obs,\ Binding}$= 1.1 ± 0.3 µM^−1^s^−1^, $k_{diss}$ = 31 ± 2 s^−1^ from the y-intercept). (**D**) The increase in fluorescence intensity of slow phase (**A**) is attributed to conformational selection. The plot of $k_{obs,\ CS}$ of this slow phase *versus* Gleevec concentration was fit to [Equation 1](#equ1){ref-type="disp-formula"} and yields $k_{1}$= 0.014 ± 0.001 s^−1^ and $k_{- 1}$= 0.011 ± 0.002 s^−1^. (**E**) Dissociation kinetics of pre-incubated solution with 5 µM Aurora A and 5 µM Gleevec measured by stopped-flow fluorescence after an 11-fold dilution of the complex yields the $k_{- 2}$ = 23.3 ± 2 s^−1^. (**F**) The macroscopic dissociation constant ($K_{D}$) of Gleevec binding to Aurora A measured by Creoptix WAVE. (**G**) Gleevec (labeled as G) binding scheme to Aurora A corresponds to a two-step binding mechanism: conformational selection followed by the physical binding step. The corresponding microscopic rate constants obtained from the global fit and calculated overall equilibrium and dissociation constants are shown. Fluorescence traces are the average of at least five replicate measurements (n \> 5), and error bars and uncertainties given in C-G denote the (propagated) standard deviation in the fitted parameter.](elife-36656-fig3){#fig3}

In order to more rigorously analyze the data and test the model, all time courses of the fluorescence changes were globally fit using the microscopic rate constants determined above as starting values ([Figure 4](#fig4){ref-type="fig"}) to the model in [Figure 3G](#fig3){ref-type="fig"}, where also the resulting microscopic rate constants are given. The lack of a conformational transition after drug binding (i.e., induced-fit step) in Aurora A should dramatically decrease drug affinity in comparison to Abl. Indeed, Gleevec binds to Aurora A with a $K_{D}$ of 24 ± 7 µM ([Figure 3F](#fig3){ref-type="fig"}) compared to the low nM affinity to Abl ([@bib3]). Two pieces of independent evidence establish that there is indeed no induced-fit step in Gleevec binding to Aurora A: (i) the calculated $K_{D}$ from the kinetic scheme is in agreement with the macroscopically measured $K_{D}$ (*cf.* [Figure 3G and F](#fig3){ref-type="fig"}), and (ii) the observed $k_{off}$ from the dilution experiment ([Figure 3E](#fig3){ref-type="fig"}) coincides with the physical dissociation rate (i.e., intercept of the binding plot, 31 ± 2 s^−1^, in [Figure 3C](#fig3){ref-type="fig"}). In summary, the lack of an induced-fit step for Gleevec binding to Aurora A is the major reason for Gleevec's weak binding, and not the DFG-loop conformation or physical drug-binding step, consistent with our earlier results ([@bib89]).

![Global fits of Gleevec binding- and dissociation-kinetics to Aurora A at 10°C.\
Fitting of kinetic traces (average, n \> 5) of the mixing of 0.5 µM Aurora A with different Gleevec concentrations at two timescales, 0.25 and 120 s, and dissociation kinetics ($k_{off}$) were performed using the KinTek Explorer software with the binding scheme in [Figure 3G](#fig3){ref-type="fig"}. Red lines show the results of the global fit to the experimental data in black.](elife-36656-fig4){#fig4}

Kinetics of Danusertib binding to Aurora A: three-step kinetics with conformational selection and an induced-fit step {#s2-3}
---------------------------------------------------------------------------------------------------------------------

Next, we wanted to shed light on why Danusertib, unlike Gleevec, binds very tightly to Aurora A. A high-resolution X-ray structure shows Danusertib bound to Aurora A's active site with its DFG-loop in the *out* conformation ([Figure 5A](#fig5){ref-type="fig"}) ([@bib33]), and to rationalize Danusertib's high affinity we measured the kinetics of Danusertib binding to Aurora A directly by stopped-flow experiments at 25°C. An increase in fluorescence intensity was observed at all Danusertib concentrations and showed double-exponential behavior ([Figure 5B](#fig5){ref-type="fig"}). The dependence of the two observed rates constants on drug concentration is linear for one of them ([Figure 5C](#fig5){ref-type="fig"}) and non-linear for the other with an apparent plateau at approximately 16 ± 2 s^−1^ ([Figure 5D](#fig5){ref-type="fig"}). The step with linear inhibitor concentration dependence corresponds to the second-order binding step, whereas a non-linear concentration dependency hints at protein conformational transitions. For a hyperbolic increase of the observed rate with substrate concentrations, one cannot *a priori* differentiate between a conformational selection and an induced fit mechanism. However, conformational selection happens before drug binding, and the intrinsic slow DFG-*in* to DFG-*out* interconversion in Aurora A revealed by Gleevec binding ([Figure 3](#fig3){ref-type="fig"}) must, therefore, be unaltered. Since the apparent rate of 16 ± 2 s^−1^ ([Figure 5D](#fig5){ref-type="fig"}) is two orders of magnitude faster, it can only reflect an induced-fit step (i.e., $k_{obs} = k_{3} + k_{- 3}$).

![Mechanism of Danusertib binding to Aurora A at 25°C.\
(**A**) Danusertib bound to the DFG-*out* conformation of Aurora A is shown highlighting important active-site residues in stick representation (PDB 2J50 \[[@bib33]\]). (**B**) The increase in fluorescence upon Danusertib binding is fitted to a double exponential. (**C**) Plot of $k_{obs,Binding}$ versus the concentration of Danusertib for the fast phase yields $k_{2}$ = 0.4 ± 0.1 μM^−1^s^−1^ and $k_{- 2}$ = 4.6 ± 3 s^−1^ and the $k_{obs,IF}$ for the slow phase (**D**) reaches a plateau around 16 ± 2 s^−1^. (**E**) Dissociation of Danusertib from Aurora A at 25°C after a 30-fold dilution of the Aurora A/Danusertib complex measured by Trp-fluorescence quenching and fitting with single exponential gives a value of $k_{- 3}$ = (3.2 ± 0.3) × 10^−4^ s^−1^. (**F**) Double-jump experiment (2 s incubation time of 1 μM Danusertib to Aurora A followed by 60 s long dissociation step initiated by a wash with buffer) was measured by Creoptix WAVE waveguide interferometry to properly define the value of $k_{- 2}$ = 6.8 ± 0.4 s^−1^. (**G**) Macroscopic dissociation constant ($K_{D}$) determined by Creoptix WAVE waveguide interferometry: surface-immobilized Aurora A was incubated with various concentrations of Danusertib (0.1 nM (black), 0.2 nM (blue), 0.4 nM (purple), 0.8 nM (red), 2.4 nM (green), 7.2 nM (pink), 21.6 nM (cyan), and 64.8 nM (orange)) and surface mass accumulation was observed until establishment of equilibrium. (**H**) A plot of the final equilibrium value versus Danusertib concentration yields a $K_{D}$ = 1.1 ± 0.4 nM. (**I**) Binding scheme of Danusertib (labeled D) highlighting a three-step binding mechanism, containing both conformational selection and induced-fit step. Red lines in (**B, F**) and black line in (**E**) are the results from fitting. Kinetic constants shown in I determined from global fitting ([Figure 6](#fig6){ref-type="fig"}). Fluorescence traces are the average of at least five replicate measurements (n \> 5), and error bars and uncertainties given in C-E, H, and I denote the (propagated) standard deviation in the fitted parameter.](elife-36656-fig5){#fig5}

So, what happened to the conformational selection step? We hypothesize that the lack of this step in our kinetic traces is due to a too small amplitude of this phase, or not observable because of photobleaching having a bigger effect at the longer measurement times. To lessen potential photobleaching, we reduced the enzyme concentration and increased the temperature to 35°C. Indeed, under these conditions, the slow DFG-*in* to DFG-*out* kinetics were observed as an increase of fluorescence intensity over time with an observed rate constant of approximately 0.1 s^−1^ ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}).

While these experiments clearly establish the three-step binding mechanism, it does not provide accurate rate constants for the conformational selection step and it cannot be observed at 25°C where all the other kinetic experiments are performed. To resolve this issue, we repeated the Aurora A--Gleevec experiment at 25°C ([Figure 5---figure supplement 2A,B](#fig5s2){ref-type="fig"}) and obtained reliable rate constants ($k_{1}$ = 0.09 ± 0.01 s^−1^ and $k_{- 1}$ = 0.06 ± 0.005 s^−1^) for the conformational selection step in Aurora A, which will be used as 'knowns' in what follows. We hypothesize that the conformational selection step reflects the interconversion between inactive/active conformations and is correlated with the DFG-*out* and -*in* position ([Figure 1](#fig1){ref-type="fig"}). The following observations support our hypothesis: (i) two crystal structures for the apo-protein show Trp277 in very different environments ([Figure 1E](#fig1){ref-type="fig"}), (ii) Danusertib has been proposed to selectively bind to the DFG-*out* conformation based on a co-crystal structure ([Figure 5A](#fig5){ref-type="fig"}) ([@bib33]), and (iii) the same slow step is observed for binding of both Gleevec and Danusertib.

Next, the dissociation kinetics for Danusertib was measured by fluorescence and appeared to be extremely slow with an observed slow-off rate of (3.2 ± 0.3) × 10^−4^ s^−1^ ([Figure 5E](#fig5){ref-type="fig"}). Rationalization of complex binding kinetics cannot be done anymore by visual inspection and kinetic intuition, which can, in fact, be misleading. In order to elucidate the correct binding mechanism and obtain accurate kinetic parameters, all kinetic traces were globally fit ([Figure 6](#fig6){ref-type="fig"}) to the three-step binding scheme ([Figure 5I](#fig5){ref-type="fig"}). Although global fitting of the binding and dissociation kinetics in KinTek Explorer delivered a value for $k_{- 2}$, evaluation of the kinetic scheme with respect to the time traces exposes that $k_{- 2}$ is not well determined from our experiments. We therefore designed a double-jump experiment to populate the AurA~out~:D state followed by dissociation to obtain more accurate information on $k_{- 2}$. Our stopped-flow machine lacks the capability to perform double mixing and, therefore, the double-jump experiment was performed using a Creoptix WAVE instrument. This label-free methodology uses waveguide interferometry to detect refractive index changes due to alteration in surface mass in a vein similar to Surface Plasmon Resonance (SPR). It is an orthogonal technique that sidesteps notable issues associated with fluorescence methods (e.g., photobleaching and inner-filter effects). In short, after immobilizing Aurora A on a WAVEchip, a high concentration of Danusertib was injected for a short, variable period of time, and dissociation was triggered by flowing buffer through the microfluidics channel to remove the drug. The dissociation kinetics fit to a single exponent with a rate constant, $k_{- 2}$, of 6.8 ± 0.4 s^−1^ ([Figure 5F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

![Global fits of Danusertib binding and dissociation kinetics to Aurora A at 25°C.\
Binding kinetics was monitored by stopped-flow fluorescence for different concentrations of Danusertib (indicated) to 0.5 µM Aurora A, and dissociation kinetics ($k_{off}^{obs}$) by Creoptix and fluorimeter (see [Figure 5](#fig5){ref-type="fig"}). Fluorescence traces are the average of at least five replicate measurements (n \> 5). Global fitting was performed using the KinTek Explorer software using the model shown in [Figure 5I](#fig5){ref-type="fig"}.](elife-36656-fig6){#fig6}

We want to discuss a few additional kinetic features. First, the observed rate constant measured in the dilution experiment ([Figure 5E](#fig5){ref-type="fig"}, $k_{- 3}$ = (3.2 ± 0.3) × 10^−4^ s^−1^) is slower than $k_{- 3}$ from the global fit ($k_{- 3}$ = (7.1 ± 0.5) × 10^−4^ s^−1^), which might seem counterintuitive. The observed rate constant was verified by an additional dilution experiment using Creoptix WAVE ($k_{- 3}$ = (2.0 ± 0.6) × 10^−4^ s^−1^, [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). The difference in the observed and microscopic rate constant can, however, be fully reconciled by considering the kinetic partitioning for the proposed scheme, as shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. Second, a powerful and independent validation of the three-step binding mechanism is obtained by comparing the measured overall $K_{D}$ of Danusertib with the calculated macroscopic $K_{D}$ from the microscopic rate constants ([Figure 5G,H,I](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}) according to [Equation 4](#equ5){ref-type="disp-formula"}, which indeed delivers values that are within experimental error. In addition, our values for $k_{2}$, $k_{- 3}$, and $K_{D}$ are in good agreement with those reported in a recent study using SPR ([@bib88]).

Our results illuminate trivial but profound principles of binding affinity and lifetime of drug/target complexes: a conformational selection mechanism always weakens the overall inhibitor affinity, while an induced-fit step tightens the affinity depending on how far-shifted the equilibrium in the enzyme/drug complex is ([Equations 2--4](#equ3 equ4 equ5){ref-type="disp-formula"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). For DFG-*out* binders (e.g., Danusertib and Gleevec), the DFG-*in* and -*out* equilibrium weakens the overall affinity 1.6-fold; however, the conformational change after drug binding results in a four orders of magnitude tighter binding for Danusertib and is the sole reason for its high affinity to Aurora A compared to Gleevec. The dissociation constants for the bimolecular binding step $K_{2}$ is very similar for both inhibitors. Finally, the lifetime of Danusertib on the target is very long because of the very slow conformational dynamics within the Aurora A/Danusertib complex ($k_{- 3}$ = (7.1 ± 0.5) × 10^−4^ s^−1^). Earlier examples of protein kinases that also show remarkable slow off-rates, presumably caused by conformational changes, include the epidermal growth factor receptors ([@bib12]; [@bib93]) and CDK8 ([@bib79]) amongst others ([@bib88]). To the best of our knowledge, we present here for the first time a detailed stopped-flow kinetics analysis for Aurora A that unequivocally shows the slow off-rate is caused by the conformational change within the drug-bound state, and not the dissociation step.

Kinetics of AT9283 binding to Aurora A -- a surprise {#s2-4}
----------------------------------------------------

We chose AT9283 as a third inhibitor to characterize the binding mechanism because it has been described as a DFG-*in* binder based on a crystal structure of AT9283 bound to Aurora A (PDB 2W1G, \[[@bib44]\]). We, therefore, anticipated that in its binding kinetics one can now detect the DFG-*out* to DFG-*in* switch. Rapid kinetic experiments of binding AT9283 to Aurora A at 25°C resulted in biphasic traces and both processes showed an increase in fluorescence over time ([Figure 7A](#fig7){ref-type="fig"}). The $k_{obs}$ for the faster phase ($k_{2}$) was linearly dependent on drug concentration reflecting the binding step ([Figure 7B](#fig7){ref-type="fig"}) and $k_{obs}$ for the slower phase ($k_{3}$) has a limiting value of 0.8 ± 0.2 s^−1^ and is attributed to an induced-fit step ([Figure 7C](#fig7){ref-type="fig"}). For the conformational selection step (i.e., DFG-*out* to DFG-*in*), a decrease in fluorescence is expected because for the reverse flip observed in the Gleevec and Danusertib experiments, a fluorescence increase was seen ([Figure 3A](#fig3){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). However, we could not find any condition (e.g., by varying temperature and ligand concentrations) where such a phase could be observed.

![Mechanism of AT9283 drug binding to Aurora A at 25°C.\
(**A**) The increase in fluorescence at 25°C upon AT9283 binding fitted to a double exponential. (**B**) The plot of $k_{obs,Binding}$ versus AT9283 concentration for the fast phase yields $k_{2}$ = 3.4 ± 0.5 μM^−1^s^−1^ and an underdetermined intercept ($k_{- 2}$) and (**C**) the $k_{obs}$ of the slow phase reaches a plateau around 0.8 ± 0.2 s^−1^. (**D**) Dilution of the Aurora A/AT9283 complex formed after 1 hour of incubation. The slow dissociation was measured by Creoptix WAVE waveguide interferometry and fitted with a double exponential with rate constants of (1.1 ± 0.02) × 10^−2^ s^−1^ and (0.1 ± 0.01) × 10^−2^ s^−1^. (**E**) Double-jump experiments (1 s incubation time of 1 μM AT9283 to Aurora A followed by 60 s long dissociation step initiated by a wash with buffer) was measured by Creoptix WAVE waveguide interferometry to properly define the value of $k_{- 2}$ = (1.0 ± 0.1) x 10^−2^ s^−1^. (**F**) Macroscopic dissociation constant ($K_{D}$) determined by Creoptix WAVE waveguide interferometry: surface-immobilized Aurora A was incubated with various concentration of AT9283 (0.03 nM (black), 0.27 nM (blue), 0.8 nM (purple), 2.4 nM (green), 7.2 nM (red), 21.6 nM (cyan), and 64.8 nM (orange)) and surface mass accumulation was observed until establishment of equilibrium. (**G**) A plot of the final equilibrium value versus AT9283 concentration yields a $K_{D}$ = 2.1 ± 1.8 nM. (**H**) Binding scheme for AT9283 (labeled AT) highlighting a four-steps binding mechanism, that contains binding to two different states, a conformational selection mechanism and an induced-fit step. Kinetic constants shown in H were determined from global fitting (see [Figure 8](#fig8){ref-type="fig"}). Fluorescence traces are the average of at least five replicate measurements (n \> 5), and error bars and uncertainties given in B, C, G and H denote the (propagated) standard deviation in the fitted parameter.](elife-36656-fig7){#fig7}

Dissociation is characterized by double-exponential kinetics ([Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). The fast phase (\~38% of the total amplitude change) decays with a rate constant of (1.1 ± 0.02) × 10^−2^ s^−1^, and the slow phase (\~62% of the total change in amplitude) has a rate constant of (0.1 ± 0.01) × 10^−2^ s^−1^. To distinguish between the reverse induced-fit step ($k_{- 3}$) and the physical dissociation step ($k_{- 2}$), a double-jump experiment was performed that unambiguously assigned the faster phase to $k_{- 2}$ ([Figure 7E](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Our attempts to globally fit all kinetic traces assuming binding to only the DFG-*in* state and using the rate constants for the DFG-loop flip from the Gleevec experiment failed ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). An extended model, where AT9283 can bind to both DFG~in/out~ conformations, followed by a common induced-fit step can also not explain the experimental kinetic traces ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). These failures, together with the lack of a detectable conformational selection step, led to a new model in which both the DFG-*in* and DFG-*out* states can bind AT9283, but only AurA~in~:AT can undergo an induced-fit step ([Figure 7H](#fig7){ref-type="fig"}). All data can be globally fit to this model ([Figure 8](#fig8){ref-type="fig"}) and the overall $K_{D}$ calculated from the corresponding microscopic rate constants (using [Equation 5](#equ6){ref-type="disp-formula"}) is in good agreement with the experimentally measured $K_{D}$ ([Figure 7F--H](#fig7){ref-type="fig"}). Finally, the 10-fold difference between the $k_{- 3}$ from the global fit ([Figure 7H](#fig7){ref-type="fig"}) and the experimentally observed slow off-rate can be reconciled by kinetic partitioning as shown in [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}.

![Global fits of AT9283 binding and dissociation kinetics to Aurora A at 25°C.\
Binding kinetics was monitored by stopped-flow fluorescence at different concentrations of AT9283 (indicated) to 0.5 µM Aurora A. Dissociation kinetics were obtained for fully equilibrated drug/kinase complex ($k_{off}^{obs}$) or for the initial encounter complex ($k_{off}^{djump}$) by using a 1 hour or a short 2 s incubation of the kinase with AT9283, respectively, before inducing dissociation by a buffer wash using Creoptix WAVE waveguide interferometry. Global fitting was performed with KinTek Explorer software using the model in [Figure 7H](#fig7){ref-type="fig"} (reduced χ^2^ = 3.2). Fluorescence traces are the average of at least five replicate measurements (n \> 5).](elife-36656-fig8){#fig8}

Crystal structures of AT9283 bound to Aurora A buttress new binding model {#s2-5}
-------------------------------------------------------------------------

In an effort to structurally verify our model we solved a crystal structure of Aurora A with AT9283 bound and indeed observed the DFG-*out* conformation (PDB 6CPG, [Figure 9B](#fig9){ref-type="fig"} and [Table 1](#table1){ref-type="table"}), in contrast to the DFG-*in* conformation as previously reported ([Figure 9A](#fig9){ref-type="fig"}) ([@bib44]). Our structure was obtained by co-crystalizing Aurora A with AT9283 and a monobody that binds to the same site as the natural allosteric activator TPX2 ([Figure 9B](#fig9){ref-type="fig"}). Binding of this monobody shifts Aurora A into an inactive conformation, with the DFG-loop in the *out* conformation. This new structure underscores the plasticity of Aurora A kinase and the ability of AT9283 to bind to a DFG-*out* state, in addition to the previously reported DFG-*in* state.

![X-ray structures of Aurora A bound to inhibitor AT9283 reveal multiple binding modes.\
(**A**) AT9283 (pink) bound to the active site of Aurora A (PDB 2W1G, \[[@bib44]\]) shows the DFG~in~-loop conformation and a salt bridge between K162 and E181. (**B**) Aurora A dimer (light and dark blue ribbon) in complex with AT9283 (pink) and inhibiting monobody (Mb, grey), showing DFG~out~-loop and broken K162 and E181 salt bridge (PDB 6CPG).](elife-36656-fig9){#fig9}

Thus, our structural and kinetic data together support that AT9283 can bind to both DFG-*in* and DFG-*out* state of Aurora A, and emphasizes the need for caution when interpreting single X-ray structures.

Inhibitors take advantage of built-in dynamics for ATP binding {#s2-6}
--------------------------------------------------------------

We finally compared the binding kinetics of the ATP-competitive inhibitors described above with the natural kinase substrate, ATP ([Figure 10](#fig10){ref-type="fig"}). In order to measure stopped-flow kinetics for ATP binding, FRET was measured by exciting Trp residues in Aurora A and detecting fluorescence transfer to the ATP-analogue mant-ATP ([@bib58]; [@bib72]). The binding of mant-ATP to Aurora A showed biphasic kinetic traces ([Figure 10A](#fig10){ref-type="fig"}) that describe the physical binding step (i.e., linear dependence on mant-ATP concentration; [Figure 10B](#fig10){ref-type="fig"}) and the induced-fit step ([Figure 10C](#fig10){ref-type="fig"}). The observed rate constant approaches a maximum value defined by the sum of $k_{3} + \ k_{- 3}$ ([Figure 10C](#fig10){ref-type="fig"}) and the intercept can be estimated to be $k_{- 3}$ and is consistent with the value obtained from the $k_{off}$ experiment ([Figure 10D](#fig10){ref-type="fig"}). We find that mant-ATP can bind to both the DFG-*in* and -*out* conformations, consistent with our nucleotide-bound crystal structures ([Figure 1A--D](#fig1){ref-type="fig"}) and recent single-molecule fluorescence spectroscopy data that indicates that nucleotide binding does not significantly affect this equilibrium ([@bib25]). To confirm the model, the kinetic data were globally fit to a two-step binding mechanism ([Figure 10G,H](#fig10){ref-type="fig"}). The calculated $K_{D}$ from the corresponding microscopic rate constants ([Figure 10H](#fig10){ref-type="fig"}) is comparable with the experimental macroscopic $K_{D}$ obtained from a titration experiment ([Figure 10E,F](#fig10){ref-type="fig"}).

![Mechanism of ATP binding to Aurora A at 10°C.\
(**A**) Binding of mant-ATP to Aurora A was followed by an increase in fluorescence with biphasic kinetics. The plot of $k_{obs}$ versus concentration of mant-ATP of the fast phase (**B**) yields $k_{2}$ = 0.8 ± 0.2 μM^−1^s^−1^ and $k_{- 2}$ = 50 ± 8 s^−1^ and the slow phase (**C**) reached a plateau around 21 ± 1 s^−1^ ($k_{3} + k_{- 3}$). (**D**) Dissociation kinetics of 10 μM Aurora A/10 μM mant-ATP complex was measured after a 11-fold dilution into buffer and yields $k_{off}^{obs}$ = 17.2 ± 1 s^−1^. (**E, F**) Macroscopic dissociation constant of Aurora A with mant-ATP measured by fluorescence energy transfer. (**E**) Emission spectra (excitation at 290 nm) of 1 μM Aurora A (green), 160 μM mant-ATP (red), and 1 μM Aurora A/160 μM mant-ATP (blue). (**F**) The change in fluorescence at 450 nm ($\Delta F^{450}$) versus mant-ATP concentrations yields $K_{D}$ = 22 ± 6 μM. (**G**) Global fitting (red) of all kinetics data (black) in KinTek Explorer to the binding scheme shown in (**H**) results in the kinetic constants given in the scheme and an overall $K_{D}$ = 48 ± 8 μM, calculated from all rate constants. Fluorescence traces are the average of at least five replicate measurements (n \> 5), and error bars and uncertainties given in B, C, D, F, and H denote the (propagated) standard deviation in the fitted parameter.](elife-36656-fig10){#fig10}

The presence of an induced-fit step for the natural substrate ATP suggests that such conformational change after ligand binding is a built-in property of the enzyme. In other words, inhibitors take advantage of the inherent plasticity of the enzyme that is required for its activity and regulation. The main difference between ATP and inhibitor binding is the rate constant for the reverse induced-fit step ($k_{- 3}$). In the case of ATP, this rate is much faster and, therefore, does not significantly increase the overall affinity. Faster conformational changes and weaker binding are of course prerequisites for efficient turnover; whereas slow conformational changes, particularly the reverse induced-fit step, are at the heart of action for an efficient drug, because it results in tight binding and a long lifetime on the target. In summary, binding of different ligands to the ATP-binding site, such as nucleotides or ATP-competitive inhibitors, is comprised of the physical binding step followed by an induced-fit step. By definition, it is the nature of the induced-fit step that varies for the different ligands since it happens as a result of ligand binding.

Discussion {#s3}
==========

Characterizing the detailed kinetic mechanisms of drug binding is not just an academic exercise but delivers fundamental knowledge for developing selective inhibitors with high affinity. An induced-fit step turns out to be key for all tight-binding inhibitors studied. From our results on Aurora A kinase presented here and earlier data on Tyrosine-kinases ([@bib3]; [@bib89]), we propose that this may be a general mechanism for different kinases and multiple inhibitors, thereby providing a platform for future computational and experimental efforts in rational drug design. Albeit, we note that verification of this proposition requires a larger sampling of small molecules and different protein kinases throughout the kinome.

The 'use' of a highly-skewed equilibrium towards E\*:D for a promising drug is logical for the following reasons: (i) it increases the affinity for the drug by this coupled equilibrium, (ii) it prolongs the residence time of the drug on the target due to the often slow reverse rate, (iii) it is specific for each drug as it happens after the drug binding, and (iv) it can add selectivity for the targets because it likely involves residues more remote from the active site. An increased drug residence time has significant pharmacological advantages as it can lead to a prolonged biological effect, a decrease of side effects, and a lower risk of metabolic drug modification. Such inhibitors have long been described as slow tight-binding inhibitors ([@bib23]; [@bib22]). The concept of the advantageous roles of induced-fit steps is based on simple thermodynamics and protein flexibility, and is, therefore, likely of relevance for drug design to other targets outside of the kinome.

Additionally, our data provides unique insight into the extensively discussed DFG flip. Combining X-ray crystallography, NMR spectroscopy and stopped-flow kinetics of drug binding establish the nature of this DFG flip both structurally, thermodynamically and kinetically, and resolves the longstanding question of its role for drug affinity and selectivity. Selective binding of a specific DFG-state by Gleevec has been first proposed as the reason for selectivity towards Abl. This conformational selection principle has ever since been at the center of drug discovery for many kinases, including Aurora A ([@bib5]; [@bib60]). Based on our results, we argue that conformational selection of the DFG-state by ATP-competitive inhibitors is a mistakenly pursued concept in drug design for the following reasons: (i) conformational selection by definition weakens the overall ligand affinity, (ii) active site binders are automatically inhibitors, therefore selective binding to a specific DFG-state has no advantage ([@bib5]; [@bib60]), (iii) kinases interconvert between both states. High selectivity gained by DFG-state selective binding could only be achieved in the scenario of a highly skewed population towards the binding-competent state for one kinase relative to all others, which is unfounded.

Our results exemplify why rational drug design is so challenging. The characterization of the complete free-energy landscape of drug binding is needed, which will require more sophisticated computational approaches guided by experimental data such as provided in our study. A good illustration of this point are the computational reports that focused on the DFG flip as a key determinant drug selectivity ([@bib5]) that now have been ruled out by our kinetic measurements. Our data suggest that future design efforts should be focusing on understanding and exploiting induced-fit steps. To this end, the different dynamic personalities of kinases or, more general, drug targets need to be investigated at atomic resolution and used to guide small-molecule design. The findings presented here are encouraging for developing selective inhibitors even for kinases with very similar folds and drug binding pockets since the action does not happen on a single structural element of the protein, but on a complex energy landscape that is unique to each kinase.

Materials and methods {#s4}
=====================

Cloning, expression and purification of dephosphorylated Aurora A (122-403) and inhibiting monobody {#s4-1}
---------------------------------------------------------------------------------------------------

Dephosphorylated Aurora A proteins were expressed and purified as described before ([@bib97]) and analyzed by mass spectrometry to confirm their phosphorylation state. The W227L mutant was generated using the QuickChange Lightning site-directed mutagenesis kit (Agilent).

U-\[^15^N\] Aurora A was obtained by growing *E. coli* BL21(DE3) (New England Biolabs) in M9 minimal medium containing 1 g/L ^15^NH~4~Cl (Cambridge Isotope Laboratories, Tewksbury, MA, USA) and 5 g/L D-glucose as the sole nitrogen and carbon source, respectively. \[^15^N\]-Trp labeled wild-type Aurora A was obtained using the standard M9 minimal medium, complemented with all amino acids (0.5 g/L) with the exception of tryptophan. One hour prior to induction, 30 mg/L of ^15^N2-L-Trp (NLM-800; Cambridge Isotope Laboratories, Tewksbury, MA, USA) was added to the medium. Similarly, to obtain samples of wild-type and W277L Aurora A containing 5-fluoro-tryptophan, bacterial growth was performed in unlabeled M9 medium containing all amino acids (0.5 g/L) except for tryptophan. One hour before protein induction, the medium was supplemented with 30 mg/L of 5-fluoro-DL-tryptophan (Sigma-Aldrich) ([@bib24]). NMR samples contained 200--300 µM Aurora A in 50 mM HEPES, pH 7.3, 50 mM NaCl, 20 mM MgCl~2~, 5 mM TCEP, 2 M TMAO and 10%(v/v) D~2~O.

Inhibiting monobody used for co-crystallization with Aurora A and AT9283 was expressed in *E. coli* BL21(DE3) cells harboring the plasmid pHBT containing His~6~-tagged-Mb. A culture of TB media containing 50 μg/mL kanamycin that was grown overnight at 37°C was added to 1 L of TB media with 50 μg/mL kanamycin to get a starting OD~600~ of \~0.2. This culture was grown at 37°C until the OD~600~ reached \~0.8. Protein expression was induced by 0.6 mM IPTG at 18°C for 13--15 h and cells were harvested by centrifugation. The cell pellet was resuspended in binding buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole, 20 mM MgCl~2~, 10% glycerol) containing 0.5 mg/mL lysozyme, 5 μg/mL DNase, and 1x EDTA-free protease inhibitor cocktail. Cells were ruptured by sonication on ice then centrifuged at 18,000 rpm at 4°C for 1 h. The supernatant was loaded onto HisTrap^TM^ HP (GE Healthcare) after filtration using 0.2 μm filtering unit. The pellet was resuspended with GuHCl buffer (20 mM Tris-HCl, pH 8.0, 6 M GuHCl) and allowed to rotate on wheel for 10 min at 4°C and spun down again. The supernatant was passed through 0.2 μm filtering unit and loaded onto HisTrap HP column previously loaded with soluble fraction and pre-equilibrated with GuHCl buffer. Refolding monobody on-column was achieved by washing the HisTrap HP column with five column volumes (CV) of GuHCl buffer, followed by 5 CV of Triton-X buffer (binding buffer + 0.1% Triton X-100), then 5 CV of β-cyclodextrin buffer (binding buffer + 5 mM β-cyclodextrin), and finally 5 CV of binding buffer. Monobody was eluted with 100% of elution buffer (binding buffer + 500 mM imidazole). The protein was dialyzed overnight in gel-filtration buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 20 mM MgCl~2~, 5 mM TCEP, 10% glycerol) in the presence of TEV protease (1:40 TEVP:Mb molar ratio). After dialysis, the TEV-cleaved monobody was passed through HisTrap HP column again. The flow-through containing TEV-cleaved monobody was collected and concentrated before loading onto Superdex 200 26/60 gel-filtration column pre-equilibrated with the gel-filtration buffer. The monobody was flash-frozen and stored in −80°C until use.

X-ray crystallography {#s4-2}
---------------------

Crystals of dephosphorylated (deP) Aurora A^122−403^ + AMPPCP were obtained by mixing 570 μM (18 mg/mL) deP Aurora A^122−403^ and 1 mM AMPPCP in a 2:1 ratio with mother liquor (0.2 M ammonium sulfate, 0.2 M Tris-HCl, pH 7.50, 30% (w/v) PEG-3350). The crystals were grown at 18°C by vapor diffusion using the hanging-drop method. The protein used for the crystallization was in storage buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10% (v/v) glycerol, 20 mM MgCl~2~, 1 mM TCEP); AMPPCP was freshly prepared before use in the same buffer. Crystals were flash-frozen in liquid nitrogen prior to shipping. Crystals of apo, deP Aurora A^122−403^ were grown at 18°C by vapor diffusion using the sitting-drop method (96-well plate). A 1:1 ratio of protein to mother liquor was obtained by combining 0.5 μL of 300 μM (10 mg/mL) deP Aurora A^122−403^ in 50 mM HEPES, pH 7.3, 500 mM ammonium acetate, 1 mM MgCl~2~, 5 mM TCEP) with 0.5 μL of 0.15 M Tris-HCl, pH 7.5, 0.15 M ammonium sulfate, 35% (w/v) PEG-3350. Crystals were soaked for 10--20 s in cryo buffer (20% (w/v) PEG-400, 20% ethylene glycol, 10% water and 50% mother liquor) before flash-freezing in liquid nitrogen. The complex between Aurora A^122−403^, inhibiting monobody (Mb) and AT9283 was crystallized at 18°C by vapor diffusion using the sitting-drop method. In short, a 1:1 ratio of protein mixture to mother liquor was obtained by combining 0.5 μL of sample \[240 μM deP Aurora A^122−403^ + 1.0 mM AT9283 + 250 μM Mb\] with 0.5 μL of mother liquor \[0.1 M Bis-Tris, pH 5.5, 0.2 M magnesium chloride, 19% (w/v) PEG-3350[\]]{.ul}. Crystals were soaked for 10--20 s in cryo buffer (17.5% (w/v) PEG-400, 17.5% ethylene glycol, 45% water and 20% mother liquor) before flash-freezing in liquid nitrogen.

Diffraction data were collected at 100 K at the Advanced Light Source (Lawrence Berkeley National Laboratory) beamlines ALS 8.2.1 (apo-AurA and AurA + Mb + AT9283) and 8.2.2 (AurA + AMPPCP) with a collection wavelength of 1.00 Å.

Data were indexed and integrated using iMOSFLM ([@bib7]) for apo/AMPPCP-bound Aurora A and Xia2 ([@bib91]) using XDS ([@bib49]) for the Aurora A/Mb/AT9283 complex, respectively. Data were scaled and merged with AIMLESS ([@bib32]), in the case of Aurora A/Mb/AT9283 two data separate data sets were merged. All software was used within the CCP4 software suite ([@bib90]).

As initial search models 1MQ4 ([@bib74]) and 3K2M ([@bib92]) were used for Aurora A and monobody, respectively, and molecular replacement was performed using Phaser ([@bib67]). The molecules were placed in the unit cell using the ACHESYM webserver ([@bib56]). Iterative refinements were carried out with PHENIX ([@bib1]), using rosetta.refine ([@bib28]) and phenix.refine ([@bib2]), and manual rebuilding was performed in Coot ([@bib30]; [@bib31]).

Structure validation was performed using MolProbity ([@bib20]) and yielded the statistics given below. The Ramachandran statistics for dephosphorylated apo (AMPPCP-bound) Aurora A are: favored: 93.65 (94.90)%, allowed 5.95 (4.71)%, outliers: 0.4 (0.39)%; 0.48 (0.0)% rotamer outliers and an all-atom clashscore of 4.45 (2.44). For the Aurora A/Mb/AT9283 complex, the Ramachandran statistics are: favored: 92.64%, allowed 7.06%, outliers: 0.3%; 0.0% rotamer outliers and an all-atom clashscore of 2.81. We note that the B-factors for the monobodies in the complex of Aurora A/Mb/AT9283 are rather high, indicating significantly flexibility in the parts that are not part of the binding interface with Aurora A.

The data collection and refinement statistics are given in [Table 1](#table1){ref-type="table"}. Structure factors and refined models have been deposited in the PDB under accession codes: 6CPE (apo Aurora A), 6CPF (Aurora A + AMPPCP) and 6CPG (Aurora A/Mb/AT9283).

All figures were generated using Chimera ([@bib75]).

NMR spectroscopy {#s4-3}
----------------

All ^19^F NMR experiments were performed at 35°C on a Varian Unity Inova 500 MHz spectrometer, equipped with a ^1^H/^19^F switchable probe tuned to fluorine (90° pulse width of 12 µs). All 1D ^19^F spectra were recorded with a spectral width of \~60 ppm and a maximum evolution time of 0.25 s. An interscan delay of 1.5 s was used with 5000 scans per transients, giving rise to a total acquisition time of 2.5 h per spectrum. To remove background signal from the probe and avoid baseline distortions, data acquisition was started after a \~100 µs delay (using the 'delacq' macro) and appropriate shifting of the data followed by backward linear prediction was performed. The data were apodized with an exponential filter (2.5 Hz line broadening) and zero-filled before Fourier transform. To improve the signal-to-noise ratio several data sets were recorded consecutively and, provided that the sample remained stable, added together after processing (two for apo Aurora A, four for Aurora A + AMPPCP, and five for W277L + AMPPCP, respectively). ^19^F chemical shifts were referenced externally to trifluoroacetic acid (TFA) at −76.55 ppm.

\[^1^H-^15^N\]-TROSY-HSQC experiments were recorded at 25°C on an Agilent DD2 600 MHz four-channel spectrometer equipped with a triple-resonance cryogenically cooled probe-head. Typically, 115--128 (^15^N) × 512 (^1^H) complex points, with maximum evolution times equal to 48.5--64 (^15^N) × 64 (^1^H) ms. An interscan delay of 1.0 s was used along with 32 or 56 scans per transient, giving rise to a net acquisition time 1.5--2.5 h for each experiment. To improve the signal-to-noise ratio several data sets were recorded consecutively and, provided that the sample remained stable, added together after processing (typically three data sets per sample).

All data sets were processed with the NMRPipe/NMRDraw software package ([@bib27]) and 2D spectra were visualized using Sparky ([@bib39]). Deconvolution of the ^19^F spectra and line shape fitting was performed using the Python package nmrglue ([@bib41]).

Kinetics experiments of Aurora A with Gleevec, Danusertib, and AT9283 {#s4-4}
---------------------------------------------------------------------

### Stopped-flow experiments {#s4-4-1}

Intrinsic tryptophan fluorescence spectroscopy was used to monitor drug binding kinetics to Aurora A. All experiments were performed at 25°C, except for the Gleevec kinetics that were measured at 10°C (unless otherwise stated) because the binding of Gleevec to Aurora A is too fast, $k_{obs,Binding}$. Stock solutions of 200 mM Danusertib, 200 mM AT9283 and 50 mM Gleevec (all purchased from Selleck Chemicals, <http://www.selleckchem.com>) were prepared in 100% DMSO were and stored at −80°C until used. Aurora A used in the kinetic experiments was dephosphorylated Aurora A as determined by mass spectrometry, Western blot and activity experiments (data not shown). The rapid kinetics were studied using a stopped-flow spectrophotometer (SX20 series from Applied Photophysics Ltd). The flow system was made anaerobic by rinsing with degassed buffer comprised of 50 mM HEPES, 50 mM NaCl, 20 mM MgCl~2~, 5 mM TCEP, 5% DMSO, pH 7.30 to minimize photobleaching. The stock solutions of Aurora A and all drugs were made anaerobic by degassing with ThermoVac (MicroCal) at the desired temperature. In general, a solution of 5 μM Aurora A was loaded in one syringe and quickly mixed with drug, prepared in the same buffer, in the other syringe (mixing ratio 1:10). A significant increase or decrease in the fluorescence intensity of Aurora A (excitation at 295 nm, emission cut-off at 320 nm) can be observed due to the drug binding. For each drug concentration, at least five replicate measurements were made and these transients were averaged. Analysis was performed by fitting the individual trace to exponential equations using Pro-Data Viewer (Applied Photophysics Ltd) or with Kinesyst 3 software (TgK Scientific) and error bars denote the standard errors as obtained from the fit. KaleidaGraph version 4.5.3 (Synergy) was used for data analysis and plotting. All kinetic data were globally fitted in KinTek Explorer software ([@bib48], [@bib47]).

Under the rapid equilibrium approximation, the binding and dissociation steps of Gleevec to Aurora A are fast compared to conformational selection, therefore the value of $k_{1}$ and $k_{- 1}$ can be estimated according to [Equation 1](#equ1){ref-type="disp-formula"}:$$k_{obs} = \ \frac{k_{- 1}}{1 + \ \left( \frac{\left\lbrack {Gleevec} \right\rbrack}{\left\lbrack {Aurora\ A} \right\rbrack + \ \left( \frac{k_{- 2}}{k_{2}} \right)} \right)} + \ k_{1}$$where $k_{1}$ and $k_{- 1}$ represent the conformational change from DFG-*in* to -*out* and vice versa, respectively. The approximate values of $k_{1}$ and $k_{- 1}$ obtained from fitting to this equation are used as starting values for the global fit.

For the 5 μM Aurora A/Gleevec complex, the release of the drug was recorded after a 11-fold dilution of the complex using the stopped-flow instrument for 0.25 s (excitation at 295 nm, emission cut-off at 320 nm) at 10°C.

### Creoptix WAVE experiments {#s4-4-2}

Double jump, slow-off, and macroscopic $K_{D}$ experiments of Aurora A with drugs were studied using a Creoptix WAVE instrument (Creoptix AG, Wädenswil, Switzerland) at 25°C. All chemicals were purchased from GE Healthcare, unless otherwise stated. The protocols in the WAVE control software for conditioning of the chip, immobilization of proteins and performing kinetics experiments were followed. In short, the polycarboxylate chip (PCH) was activated by injection of a 1:1 mixture with final concentrations of 200 mM N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide (EDC) and 50 mM N-hydroxysuccinimide (NHS), followed by streptavidin immobilization (50 μg/mL in 10 mM sodium acetate pH 5.0). Unreacted sites on the chip were blocked with 1 M ethanolamine pH 8.0. For all activation, immobilization and passivation steps 0.2x HBS-EP was used as running buffer with a flowrate of 10 μL/min and an injection duration of 420 s on both channels 1 and 2.

Biotinylated T288V variant that mimics dephosphorylated Aurora A was used for experiments performed on the Creoptix WAVE instrument. The activity of T288V with substrate Lats2, the macroscopic $K_{D}$ and slow-off rate of Danusertib were the same as wild-type (data not shown). Biotinylated T288V Aurora A (70 μg/mL) was immobilized on the PCH-streptavidin chip with 10 μL/min injection and 15 s injection duration over channel 1 only (channel 2 was used as reference channel). All experiments were run in 50 mM HEPES, 50 mM NaCl, 20 mM MgCl~2~, 5 mM TCEP, 0.03 mg/mL BSA, 0.005% Tween-20, pH 7.30 as running buffer. Binding experiments were evaluated over a range of Danusertib (0.13--66.67 nM), AT9283 (0.03--64.8 nM), and Gleevec (0.37--40 μM) concentrations. Gleevec binding experiments contained 5% DMSO in the running buffer (see above) to enhance Gleevec's solubility. Double-jump experiments of Aurora A/drugs were performed by injecting 1 μM Danusertib or AT9283 with 0.2, 0.4, 0.8, and 2 s injection duration for Danusertib and 1 and 3 s injection duration for AT9283 followed by a 60 s dissociation duration per injection. The slow-off experiments were performed by injecting 5 μM Danusertib or AT9283 with 5--10 s injection duration (to fully saturate Aurora A) followed by a 180 s injection of buffer to remove the excess drug and the dissociation was measured for a duration of 10800 s.

### Spectrofluorometer experiments {#s4-4-3}

The spectrofluorometer FluoroMax-4 (Horiba Scientific) with temperature controller was used to study the slow-off rate of Aurora A with Danusertib at 25°C. For this experiment, a solution containing 30 nM Aurora A and 30 nM Danusertib was pre-incubated for an hour, before diluting 30-fold into degassed buffer (ratio 1:30). A significant decrease in the fluorescence intensity of Aurora A (excitation at 295 nm, emission at 340 nm) can be seen due to the Danusertib release. The fluorescence signal was recorded every 160 s for a duration of six hours using the photobleaching minimization option that will close the shutter after each acquisition. A control experiment was performed, using the same experimental conditions, but without drug in order to account for photobleaching.

Overall dissociation constant calculated from intrinsic rate constants {#s4-5}
----------------------------------------------------------------------

In the following equations, $K_{1}$, $K_{2}$, $K_{3}$ and $K_{4}$ are equal to:$$\begin{matrix}
K_{1} & {= \frac{k_{- 1}}{k_{1}}} \\
K_{2} & {= \frac{k_{- 2}}{k_{2}} = \frac{k_{off}}{k_{on}}} \\
K_{3} & {= \frac{k_{- 3}}{k_{3}}} \\
K_{4} & {= \frac{k_{- 4}}{k_{4}}} \\
\end{matrix}$$

Conformational selection followed by inhibitor binding:$$\begin{matrix}
{E_{in}\underset{k_{- 1}}{\overset{k_{1}}{\rightleftharpoons}}E_{out}} & {+ {\ I\ \underset{k_{off}}{\overset{k_{on}}{\rightleftharpoons}}E_{out} \cdot I}} & \\
{K_{1}} & {\!\!\!\!\!\! K_{2}} & {K_{D} = (K_{1} + 1) \ast K_{2}} \\
\end{matrix}$$

Inhibitor binding followed by an induced-fit step:$$\begin{matrix}
{E_{out} + \ I\underset{k_{off}}{\overset{k_{on}}{\rightleftharpoons}}E_{out} \cdot I} & {\underset{k_{- 3}}{\overset{k_{3}}{\rightleftharpoons}}E_{out}^{\ast} \cdot I} & \\
{\  K_{2}} & {\!\!\!\!\!\!\!\!\!\!\! K_{3}\quad\quad} & {K_{D} = \frac{K_{2} \ast K_{3}}{(K_{3} + 1)}} \\
\end{matrix}$$

Conformational selection followed by inhibitor binding and an induced-fit step:$$\begin{matrix}
{E_{in}\underset{k_{- 1}}{\overset{k_{1}}{\rightleftharpoons}}E_{out} + I} & {\underset{k_{off}}{\overset{k_{on}}{\rightleftharpoons}}E_{out} \cdot I} & {\underset{k_{- 3}}{\overset{k_{3}}{\rightleftharpoons}}E_{out}^{\ast} \cdot I} & \\
{\!\!\!\!\!\!\! K_{1}\quad\quad} & {\!\!\!\!\!\!\!\!\!\!\! K_{2}\quad\quad} & {\!\!\!\!\!\!\!\!\!\!\! K_{3}\quad\quad} & {K_{D} = \frac{(K_{1} + 1) \ast K_{2} \ast K_{3}}{K_{3} + 1}} \\
\end{matrix}$$

Conformational selection mechanism, followed by inhibitor binding to both DFG-*in* and -*out* state, but an induced-fit step only occurs in the DFG-*in* state:$$\begin{matrix}
{\quad{E_{out}\underset{k_{- 1}}{\overset{k_{1}}{\rightleftharpoons}}E_{in} + I}} & {\underset{k_{off}}{\overset{k_{on}}{\rightleftharpoons}}E_{in} \cdot I} & {\underset{k_{- 3}}{\overset{k_{3}}{\rightleftharpoons}}E_{in}^{\ast} \cdot I} & \\
{\!\!\!\!{K_{4}\frac{\downharpoonleft \! \upharpoonright}{E_{out} \cdot I}}\; K_{1}} & { K_{2}} & { K_{3}} & {K_{D} = \frac{(K_{1} + 1) \ast K_{2} \ast K_{3} \ast K_{4}}{K_{1} \ast K_{2} \ast K_{3} + K_{3} \ast K_{4} + K_{4}}} \\
\end{matrix}$$

The uncertainties in the calculated dissociation constant parameter using the equations above are obtained using standard error propagation.

Aurora A binding to mant-ATP {#s4-6}
----------------------------

FRET using intrinsic tryptophan fluorescence is used to monitor mant-ATP (obtained from Jena Bioscience) binding kinetics to Aurora A at 10°C. In the binding experiment or $k_{on}$, increasing concentration of mant-ATP were quickly mixed to 0.5 µM Aurora A (ratio 1:10, excitation at 295 nm, emission cut-off at 395 nm). In the experiment to measure the release of mant-ATP or $k_{off}$, 10 µM/10 µM Aurora A/mant-ATP complex was diluted with buffer (ratio 1:10). A significant decrease in the fluorescence intensity of Aurora A (excitation at 295 nm, emission cut-off at 395 nm) can be seen due to the mant-ATP release.

Macroscopic dissociation constant experiments {#s4-7}
---------------------------------------------

Fluorescence titration experiments were measured using FluoroMax-4 spectrofluorometer (Horiba Scientific). Increasing amounts of Aurora A/Danusertib complex (4 nM Aurora A and 150 nM Danusertib) or Aurora A/mant-ATP (1 µM Aurora A and 2 mM mant-ATP) were titrated into an Aurora A solution (4 nM and 1 µM Aurora A for experiments with Danusertib and mant-ATP, respectively). To measure Danusertib affinity, the excitation wavelength was 295 nm (5 nm bandwidth) and emission spectra were recorded from 310 to 450 nm (20 nm bandwidth) in increments of 2 nm and the temperature was maintained at 25°C. For the mant-ATP experiment, the dissociation constant was measured at 10°C using fluorescence energy transfer from tryptophan residues in Aurora A to mant-ATP by setting the excitation wavelength to 290 nm (5 nm bandwidth) and collecting the emission intensity from 310 to 550 nm (5 nm bandwidth) in increments of 2 nm. A control experiment in the absence of Aurora A was performed using the same experimental settings and used to correct for the mant-ATP interference. In all experiments, a 5 min equilibration time was used after each addition of Aurora A/Danusertib complex or Aurora A/mant-ATP complex.

The fluorescence intensity at 368 nm versus Danusertib concentration or the change in fluorescence at 450 nm ($\Delta F^{450}$) versus mant-ATP concentration was fitted to [Equation 6](#equ7){ref-type="disp-formula"} using Levenberg-Marquardt nonlinear fitting algorithm included in KaleidaGraph to obtain the $K_{D}$.$$F = F_{0} + A \cdot \frac{\left\lbrack I \right\rbrack + \left\lbrack E_{t} \right\rbrack + K_{D} - \sqrt{\left( {\left\lbrack I \right\rbrack + \left\lbrack E_{t} \right\rbrack + K_{D}} \right)^{2} - 4 \cdot \left\lbrack E_{t} \right\rbrack \cdot \left\lbrack I \right\rbrack}}{2 \cdot \left\lbrack E_{t} \right\rbrack}$$

$F$ and $F_{0}$ are the fluorescence and initial fluorescence intensities, respectively. $\left\lbrack I \right\rbrack$ and $\left\lbrack E_{t} \right\rbrack$ are the total concentration of the drug or mant-ATP and the Aurora A, respectively.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Dynamics of human protein kinases linked to drug selectivity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Philip Cole as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal his identity: John Kuriyan (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript by the Kern group presents an important advance in our understanding of why different ATP-competitive kinase inhibitors have dramatically different binding properties for the same kinase. The authors use an elegant combination of kinetic measurements using intrinsic tryptophan fluorescence, NMR, and X-ray crystallography, to identify discrete conformational states of the Ser/Thr kinase Aurora A, and to correlate the adoption of these states with drug binding. While the flipping of the DFG motif in the activation loop of kinases is often noted as a commonly-observed conformational change that impacts drug binding, here, the authors identify additional conformational changes, on top of the DFG flip, that impact the fast or slow off-rates of different drugs for Aurora A. The nature of these conformational changes is not defined in the paper, but the paper makes an important contribution by establishing these additional conformational changes are important for Aurora, as well as for the cytoplasmic tyrosine kinases for which the Kern group first established this property.

Collectively, these experiments shed light on the nuanced interplay of inhibitor binding and kinase dynamics, and provide an experimental approach to dissect kinetic mechanisms of drug binding that could play an important role in future kinase inhibitor design strategies. The main conclusion is that the dynamical response to inhibitor binding that was established earlier (by this group) for the tyrosine kinases Src and Abl also applies to Aurora, a Ser/Thr kinase. As such, this work merits publication in *eLife*, after revision. While revising the manuscript, the authors should pay careful attention to placing this work in proper context within what is already known and appreciated about how kinases respond to inhibitors. Also, the work would be strengthened by being clearer about what is actually learned, rather than overstating the conclusions. This work advances the field in an important way, and would be valued all the more if it represented past insights more appropriately. In this regard, the title of the paper should be made more specific, and not imply that a broad cross-section of kinases have been studied, or that a single mechanism has been uniquely defined.

Essential revisions:

1\) The way the paper is written the reader may get the mistaken impression that the DFG conformational change is irrelevant (or less important) for drug selectivity.

Indeed, although previous work from the Kern group established that an induced conformational change after Gleevec binding to Abl, but not to Src, contributes to differential inhibition of these two kinases, it remains true that Gleevec can only bind to either of these kinases in the DFG-out state. Prior to the original observation of the DFG flip in Abl kinase, by the Kuriyan group, the DFG-out state was not known to be an accessible conformational state of protein kinases, let alone one that could bind a drug.

Related to this point, the authors aim to describe a new, generalizable paradigm for kinase-inhibitor interactions, one that decreases the importance of the DFG-flip. While this is intriguing, it awaits further analysis of the conformational landscape of other kinases, in the presence and absence of inhibitors. The authors should consider rephrasing sections so that they do not downplay the significance of the DFG-out conformation in drug binding. In other words, nothing that has followed since the original crystal structure of Abl bound to Gleevec (Schindler et al.) has overturned the conclusion drawn by the Kuriyan group that Gleevec specifically recognizes a DFG-flipped conformation of the kinase. What is now appreciated is that the DFG-flip is not the only requirement for drug binding, and many (if not all) kinases can undergo this conformational change. The way this paper is written, this is not obvious. Also, at points where the \"seminal\" observation of Gleevec selectivity is described, the authors cite much more recent papers, rather than the original discoveries. The work from the Kuriyan group is cited, but in a throw-away sentence in the middle of the paper.

2\) The authors somewhat mischaracterize our general understanding of the role of activation loop phosphorylation. While it is true that many seminal studies have established a correlation between activation loop phosphorylation and the adoption of an active, rather inactive configuration, several studies have actually suggested that this is a conformational selection, rather than induced fit, phenomenon. Indeed, some protein kinases lacking activation loop phosphorylation have been crystalized in an active conformation, and molecular dynamics calculations suggest that this the active state is accessible to the protein kinases in the absence of activation loop phosphorylation, albeit at a higher energetic cost (see work by Benoit Roux, and also Vijay Pande). Most recently, the work by Ruff et al. on Arora A (2018), the same kinase studied in this report, has convincingly shown that activation loop phosphorylation does not preclude access to an inactive conformation in this kinase.

3\) The issue of an unphosphorylated kinase domain adopting different conformations in crystals is presented as surprising, but this is well appreciated. These points were also made in Levinson et al. (2006) (not cited here) where the authors present \"crystal structures of the Abl kinase domain bound to substrate-mimicking ATP analog-peptide conjugates that represent four distinct conformations of the unphosphorylated kinase domain\". The idea that two different conformations can be found in the same crystal is also not new. Crystallographically, this was noted in Seeliger et al., 2007, who report a crystal structure in which two molecules of Src are found, one bound to Gleevec, and the other in an active conformation. Given these points, the authors could consider rewording parts of the first two paragraphs of the Results section so as not to suggest that their observation of an active-like unphosphorylated kinase is unexpected.

4\) The authors introduce the paper by pointing out that it remains a challenge to understand why certain drugs are selective for individual or few kinases out of the whole kinome (\~500 related enzymes). They present the work in this manuscript with the intention of solving this problem. The work presented here, however, only explains how different inhibitors interact with one individual kinase, not why the same inhibitor might have differential binding properties for different kinases. This crossing of concepts is misleading to the readers.

5\) The fact that kinases can undergo a conformational change that results in remarkably slow off-rates for inhibitors has been appreciated from work such as the binding of Tykerb to EGFR (Wood et al., 2004). This point should be made in the revised paper, and the appropriate papers cited.

6\) The concept that the DFG flip is not the sole determining factor in determining the binding of Gleevec to Abl vs Src was first established by determining the structures of high-affinity compounds bound to Src in a DFG-flipped conformation by Seeliger et al. 2009, Cancer Research and Dar et al., 2008, Chemical Biology. Neither paper is cited in the present paper, which gives readers the misleading impression that the field was not aware of this fact prior to the Kern contributions.

7\) As noted earlier, a related paper was just published in *eLife* by Ruff et al. (2018), examining the impact of activation loop phosphorylation on kinase dynamics and the DFG-flip. In that report, the investigators conclude that Aurora A can sample the DFG-in and DFG-out states with and without activation loop phosphorylation, and that another drug, SNS-314 induces further conformational changes upon binding the DFG-in state of Arora A. These results are pertinent to several points in the manuscript reviewed here and should be discussed.

8\) The paper relies heavily on elegant kinetic studies using stopped-flow fluorescence measurements, and these measurements yield multi-step kinetic models for drug binding. These models are crucial to this study, but multi-step reactions are hard to intuitively understand. It would be worthwhile for the authors to model and graphically depict the outcomes of several scenarios varying one or two parameters in their kinetic models at a time, to show why, for example, conformational selection between the DFG-in and DFG-out states does not substantially contribute to Danusertib binding, whereas the induced fit step does. Similar analyses could be done for the other inhibitors as well and would greatly facilitate the readers\' understanding of these important concepts.

9\) It might be interesting to examine the kinetic mechanism of one drug against a few different kinases. The authors already did this in their previous paper, comparing Gleevec binding with Src and Abl, and now with Aurora A in this manuscript. To infer that their observed induced fit phenomena underly a general principle of drug binding, perhaps the authors could compare Danusertib binding kinetics for Aurora A with a few other kinases. If this is not feasible, then the revised manuscript should state that the generality of the principles awaits further study.
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Author response

> \[...\] While revising the manuscript, the authors should pay careful attention to placing this work in proper context within what is already known and appreciated about how kinases respond to inhibitors. Also, the work would be strengthened by being clearer about what is actually learned, rather than overstating the conclusions. This work advances the field in an important way, and would be valued all the more if it represented past insights more appropriately. In this regard, the title of the paper should be made more specific, and not imply that a broad cross-section of kinases have been studied, or that a single mechanism has been uniquely defined.

As described in more detail below, we have edited manuscript to be more nuanced and attempted to acknowledge the vast amount of literature in the protein kinase field, following the suggestions by the reviewers. We made the title more specific: "Dynamics of human protein kinase Aurora A linked to drug selectivity".

> Essential revisions:
>
> 1\) The way the paper is written the reader may get the mistaken impression that the DFG conformational change is irrelevant (or less important) for drug selectivity.
>
> Indeed, although previous work from the Kern group established that an induced conformational change after Gleevec binding to Abl, but not to Src, contributes to differential inhibition of these two kinases, it remains true that Gleevec can only bind to either of these kinases in the DFG-out state. Prior to the original observation of the DFG flip in Abl kinase, by the Kuriyan group, the DFG-out state was not known to be an accessible conformational state of protein kinases, let alone one that could bind a drug.
>
> Related to this point, the authors aim to describe a new, generalizable paradigm for kinase-inhibitor interactions, one that decreases the importance of the DFG-flip. While this is intriguing, it awaits further analysis of the conformational landscape of other kinases, in the presence and absence of inhibitors. The authors should consider rephrasing sections so that they do not downplay the significance of the DFG-out conformation in drug binding. In other words, nothing that has followed since the original crystal structure of Abl bound to Gleevec (Schindler et al.) has overturned the conclusion drawn by the Kuriyan group that Gleevec specifically recognizes a DFG-flipped conformation of the kinase. What is now appreciated is that the DFG-flip is not the only requirement for drug binding, and many (if not all) kinases can undergo this conformational change. The way this paper is written, this is not obvious. Also, at points where the \"seminal\" observation of Gleevec selectivity is described, the authors cite much more recent papers, rather than the original discoveries. The work from the Kuriyan group is cited, but in a throw-away sentence in the middle of the paper.

The reviewers are correct that the DFG-state is important for whether a drug can or cannot bind to the kinase due to steric clash. The seminal work by the Kuriyan lab on Gleevec binding to Abl and Src, and other examples by various research groups, have provided unequivocal evidence for this fact. We certainly did not intend to downplay any of these contributions nor the significance of the orientation of DFG-motif in the physical drug-binding step. We had elected to cite reviews and several of the more recent papers, but the reviewers are correct that we should include more of the original research papers. We have now added these references. A conformational-selection mechanism alone has however proved insufficient to explain drug affinity and selectivity, and in fact, will by definition weaken the overall affinity. We show here (and in our earlier work on Gleevec) that conformational dynamics after drug binding plays the crucial role in understanding overall selectivity and affinity. We realize that our original wording created some misunderstanding and have edited the manuscript to reflect this sentiment more clearly; in the introduction it now states:

"Seminal work by the Kuriyan lab demonstrated that Gleevec can only bind to an inactive DFG (for Asp-Phe-Gly) loop conformation in the "out-conformation" due to steric clash of the active, DFG-in conformation (Nagar et al., 2002; Schindler et al., 2000; Seeliger et al., 2007). \[...\] Recent quantitative binding kinetics combined with ancestral sequence reconstruction put forward a mechanism where an induced-fit step after drug binding is the key determinant for Gleevec's selectivity (Agafonov, Wilson, Otten, Buosi, and Kern, 2014; Wilson et al., 2015), and fully recapitulates the binding affinities."

> 2\) The authors somewhat mischaracterize our general understanding of the role of activation loop phosphorylation. While it is true that many seminal studies have established a correlation between activation loop phosphorylation and the adoption of an active, rather inactive configuration, several studies have actually suggested that this is a conformational selection, rather than induced fit, phenomenon. Indeed, some protein kinases lacking activation loop phosphorylation have been crystalized in an active conformation, and molecular dynamics calculations suggest that this the active state is accessible to the protein kinases in the absence of activation loop phosphorylation, albeit at a higher energetic cost (see work by Benoit Roux, and also Vijay Pande). Most recently, the work by Ruff et al. on Arora A (2018), the same kinase studied in this report, has convincingly shown that activation loop phosphorylation does not preclude access to an inactive conformation in this kinase.

We certainly did not intend to mischaracterize the understanding of the role of activation loop phosphorylation. We describe the general notion from X-ray crystallography data that unphosphorylated, apo Aurora A kinase is mostly found in an inactive conformation, whereas an active conformation is observed when the activation loop is phosphorylated or upon TPX2 binding. Whether the interconversion from an inactive to the active conformation happens before (i.e., conformational selection) or after (i.e., induced fit) phosphorylation of the kinase is a question of flux. This can only be addressed by measuring the kinetics of Aurora A phosphorylation in concert with its conformational interconversion between the inactive and active conformation. In other words, a kinetic flux analysis for protein phosphorylation would be required, similarly to the kinetic flux analysis performed here for the inhibitors. This topic is outside of the scope of this manuscript and not addressed here, and, to the best of our knowledge, such kinetics analysis has not been reported thus far.

We fully agree with the reviewers that in the absence of phosphorylation the protein can sample an active conformation. In fact, the data in our manuscript on the dephosphorylated kinase provides three lines of evidence for this: (1) structures of apo and AMPPCP-bound Aurora A crystallized in the active conformation, (2) stopped-flow fluorescence data showing the presence of a conformational-selection mechanism, and (3) NMR spectra indicating exchange between different states. We have expanded the section describing the computational efforts and included more references:

"Owing to the reported importance of the DFG flip for activity, regulation and drug design, there have been extensive efforts to characterize this conformational equilibrium by computation (Badrinarayan and Sastry, 2014; Barakat et al., 2013; Meng, Lin, and Roux, 2015; Meng, Pond, and Roux, 2017; Sarvagalla and Coumar, 2015; Shukla, Meng, Roux, and Pande, 2014). The general notion of these computational studies is that in the absence of phosphorylation the inactive form of the kinase is most favored, in agreement with experimental evidence. Nevertheless, short-lived excursions to the active state are observed."

More recently, experiments on Aurora A kinase described by Cyphers et al. (2017), Gilburt et al. (2017) and Ruff et al. (2018) report on the position of the activation loop of (un)phosphorylated kinase in the absence/presence of various small molecules. For monitoring the DFG-loop, an IR probe was chemically incorporated into a position that hydrogen-bonds to the DFG-loop in the wild-type protein, resulting in a large reduction in kinase activity. We therefore opt for caution in the interpretation of these data in respect of the DFG-loop conformation for the wild-type protein. Our results are consistent with their observations in that Aurora A samples several activation loop conformations in its unphosphorylated form and that binding of nucleotides merely affects the equilibrium constant (Cyphers et al., 2017). Since our manuscript only pertains to dephosphorylated Aurora A, we have no data to compare to the experiments described by Gilburt et al. and Ruff et al.that report on phosphorylated Aurora A.We have extended the first paragraph of the Results section to include these more recent papers:

"X-ray structures, however, provide merely static snapshots of possible kinase conformations that do not necessarily reflect the situation in solution. In fact, recent experimental data postulate that phosphorylation of Aurora A does not "lock" the kinase in the active conformation, and that the activation-loop still exhibits conformational dynamics (Gilburt et al., 2017; Ruff et al., 2018). On the other hand, X-ray crystallography provides high-resolution structural data that cannot readily be obtained from FRET or EPR and IR spectroscopy."

> 3\) The issue of an unphosphorylated kinase domain adopting different conformations in crystals is presented as surprising, but this is well appreciated. These points were also made in Levinson et al. (2006) (not cited here) where the authors present \"crystal structures of the Abl kinase domain bound to substrate-mimicking ATP analog-peptide conjugates that represent four distinct conformations of the unphosphorylated kinase domain\". The idea that two different conformations can be found in the same crystal is also not new. Crystallographically, this was noted in Seeliger et al., 2007, who report a crystal structure in which two molecules of Src are found, one bound to Gleevec, and the other in an active conformation. Given these points, the authors could consider rewording parts of the first two paragraphs of the Results section so as not to suggest that their observation of an active-like unphosphorylated kinase is unexpected.

We fully agree with the reviewers that our choice of words could be misconstrued. We have reworded the paragraph owing to the well-known fact that different conformations out of the structural ensemble have been captured by X-ray crystallography on a number of systems before. We thank the reviewers for pointing this out and we have included additional references.

"Our results are consistent with other crystallographic studies on wild-type, dephosphorylated Aurora A in its apo or nucleotide bound state, where the kinase was also found in the active conformation (Gustafson et al., 2014; Janecek et al., 2016; Nowakowski et al., 2002)."

We further clarify that in our case we have "Two crystals from the same crystallization well", not two different conformations within one crystal, or two molecules in the asymmetric unit that are different in structure.

> 4\) The authors introduce the paper by pointing out that it remains a challenge to understand why certain drugs are selective for individual or few kinases out of the whole kinome (\~500 related enzymes). They present the work in this manuscript with the intention of solving this problem. The work presented here, however, only explains how different inhibitors interact with one individual kinase, not why the same inhibitor might have differential binding properties for different kinases. This crossing of concepts is misleading to the readers.

The reviewers are correct that the work presented here explains how different inhibitors interact with Aurora A kinase and not the whole kinome. We note, however, that the inhibitor Gleevec was used both for Aurora A and in our earlier work on Src, Abl, and their evolutionary intermediates (Agafonov et al., 2014; Wilson et al., 2015). We find it interesting that the physical binding step of Gleevec to these different kinases is virtually unaltered and that the major contribution for a tight-binder is due to the induced-fit step after binding. The critical role of the dynamics in the drug-bound state holds true when looking at the binding of different small molecules to the Aurora A kinase. We fully agree that the presented results raise the interest to extend our knowledge of the interaction of other inhibitors with a broader cross-section of the kinome (see also point 9, added to the Discussion), which we hope to provoke with our work. We thank the reviewers for bringing up our misleading wording. We have changed the text accordingly and made the comparison for Gleevec binding to the different protein kinases clearer in the Results section.

> 5\) The fact that kinases can undergo a conformational change that results in remarkably slow off-rates for inhibitors has been appreciated from work such as the binding of Tykerb to EGFR (Wood et al., 2004). This point should be made in the revised paper, and the appropriate papers cited.

While we referred in the Discussion section to literature reviews on the "drug-target residence time", we can certainly make this more specific and describe some of the earlier work on kinases. We thank the reviewers for pointing this out and have included this in the revised manuscript in the Results section when describing the danusertib experiments:

"Earlier examples of protein kinases that also show remarkable slow off-rates, presumably caused by conformational changes, include the epidermal growth factor receptors (Berezov, Zhang, Greene, and Murali, 2001; Wood et al., 2004) and CDK8 (Schneider, Bottcher, Huber, Maskos, and Neumann, 2013) amongst others (Willemsen-Seegers et al., 2017). To the best of our knowledge, we present here for the first time a detailed stopped-flow kinetics analysis for Aurora A that unequivocally shows the slow off-rate is caused by the conformational change within the drug-bound state, and not the dissociation step."

> 6\) The concept that the DFG flip is not the sole determining factor in determining the binding of Gleevec to Abl vs Src was first established by determining the structures of high-affinity compounds bound to Src in a DFG-flipped conformation by Seeliger et al. 2009, Cancer Research and Dar et al., 2008, Chemical Biology. Neither paper is cited in the present paper, which gives readers the misleading impression that the field was not aware of this fact prior to the Kern contributions.

It was indeed recognized earlier that the DFG-flip alone could not rationalize the binding of Gleevec to Abl/Src, and other hypotheses were put forward. We had no intent to represent this otherwise and, for clarification, we have modified the introduction to reflect this (see under point 1). Here, we provide now the relative contribution of the individual steps in the coupled equilibria for the binding of inhibitors to Aurora A via quantitative kinetic experiments.

> 7\) As noted earlier, a related paper was just published in eLife by Ruff et al. (2018), examining the impact of activation loop phosphorylation on kinase dynamics and the DFG-flip. In that report, the investigators conclude that Aurora A can sample the DFG-in and DFG-out states with and without activation loop phosphorylation, and that another drug, SNS-314 induces further conformational changes upon binding the DFG-in state of Arora A. These results are pertinent to several points in the manuscript reviewed here and should be discussed.

See our answer to point 2.

> 8\) The paper relies heavily on elegant kinetic studies using stopped-flow fluorescence measurements, and these measurements yield multi-step kinetic models for drug binding. These models are crucial to this study, but multi-step reactions are hard to intuitively understand. It would be worthwhile for the authors to model and graphically depict the outcomes of several scenarios varying one or two parameters in their kinetic models at a time, to show why, for example, conformational selection between the DFG-in and DFG-out states does not substantially contribute to Danusertib binding, whereas the induced fit step does. Similar analyses could be done for the other inhibitors as well and would greatly facilitate the readers\' understanding of these important concepts.

We agree with the reviewers that the fine details of multi-step reactions and coupled-equilibria are often not intuitive to understand. The contribution of a conformational-selection and induced-fit step on the overall dissociation constant can be appreciated in a quite straightforward manner from Equation 4 (i.e., thermodynamics of coupled equilibria) in the manuscript:

1\) a conformational selection mechanism weakens the overall affinity by the amount of sampling of the binding-incompetent state

2\) an induced-fit step tightens the overall affinity by the amount of "right-shifting" the equilibrium to the E\*:D state.

We demonstrate this graphically in [Author response image 1](#respfig1){ref-type="fig"} for the binding of danusertib to Aurora A, as suggested by the reviewers. In panels A and B, we change the equilibrium constant for the conformational selection mechanism (K~1~) or induced-fit step (K~3~) by two orders of magnitude in both directions, starting from unity. For comparison, the K~D~ value is shown when only the physical drug-binding step would be present (the value for K~2~, 14 𝜇M, is taken from our stopped-flow experiments, see Figure 5). In panel C we show the effect of changing the same equilibrium constants for the combined, four-state model (see Figure 5I, Equation 4). Both K~1~ and K~3~ are changed by two orders of magnitude around the experimentally determined values of 0.67 and 3.7·10^-5^, respectively, and the overall K~D~ is plotted on the y-axis. If the reviewers feel that this would be useful to include as a figure supplement, we would be happy to do so. Alternatively, should we move Equation 4 into the main text?
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> 9\) It might be interesting to examine the kinetic mechanism of one drug against a few different kinases. The authors already did this in their previous paper, comparing Gleevec binding with Src and Abl, and now with Aurora A in this manuscript. To infer that their observed induced fit phenomena underly a general principle of drug binding, perhaps the authors could compare Danusertib binding kinetics for Aurora A with a few other kinases. If this is not feasible, then the revised manuscript should state that the generality of the principles awaits further study.

Agreed and we revised the manuscript accordingly:

"From our results on Aurora A kinase presented here and earlier data on Tyrosine-kinases (Agafonov et al., 2014; Wilson et al., 2015), we propose that this may be a general mechanism for different kinases and multiple inhibitors, thereby providing a platform for future computational and experimental efforts in rational drug design. Albeit, we note that verification of this proposition requires a larger sampling of small molecules and different protein kinases throughout the kinome."

We hope that this manuscript will trigger similar studies in many labs working on exciting aspects of many different kinases/inhibitor interactions to test how general this concept is (we speculate it will be quite general).

[^1]: These authors contributed equally to this work.
